While BASF has surpassed its savings targets, streamlined its portfolio, and set its agricultural unit on a path to independence, its shares continue to face significant pressure. A noticeable gap has emerged between the chemical giant’s operational progress and the prevailing market sentiment.
Shareholder Meeting to Pave the Way for Key Moves
Investor attention is focused on the Annual General Meeting scheduled for April 30 in Mannheim. Shareholders are expected to approve two critical items. The first is a dividend payment of €2.25 per share, amounting to a total distribution of nearly €2 billion. The second, and more strategically significant, is the formal approval to spin off the company’s Agricultural Solutions business.
This separation is the cornerstone of BASF’s strategic realignment. Beginning May 1, a new management board will take charge of the unit to steer it through the transition. The goal is to list the agricultural entity as a standalone company on the Frankfurt Stock Exchange by 2027, with BASF retaining a majority stake. The scale of this division is substantial, having generated sales of €9.8 billion in 2024.
Financial Discipline and Portfolio Refocus
Concurrent with these strategic shifts, BASF is demonstrating financial discipline through its ongoing share buyback program. By mid-March, the company had already repurchased 17.5 million shares for €789 million. This activity is part of a larger €1.5 billion program running through June 2026, which itself falls under a broader €4 billion framework extending to 2028.
Should investors sell immediately? Or is it worth buying BASF?
The company remains committed to portfolio simplification. Recent divestments include the sale of its Aseptrol technology portfolio to Oxidium Technologies. This follows earlier transactions, such as the disposal of hydrosulfite plants and the optical brighteners business, underscoring a consistent effort to sharpen the corporate focus.
Operational Gains Overshadowed by Forecast Concerns
Despite these efforts, BASF faces persistent headwinds. The company has even expanded its cost-saving target to €2.3 billion, which is €200 million more than initially planned. However, this has not been enough to fully reassure the market.
A key point of contention is the 2026 EBITDA forecast communicated in February, which ranges between €6.2 billion and €7.0 billion. The upper limit of this guidance narrowly missed the analyst consensus estimate of €7.02 billion. Several external factors continue to weigh on performance, including a weaker U.S. dollar, subdued demand from key customer industries like automotive and construction, and structurally high energy costs in Germany.
Reflecting this cautious environment, BASF’s stock is down approximately 10% year-to-date and trades nearly 12% below its 52-week high. The upcoming Annual General Meeting will serve as a crucial gauge of investor confidence. The vote on the agricultural spin-off, in particular, is poised to be the definitive test of market sentiment towards BASF’s evolving strategy.
Ad
BASF Stock: Buy or Sell?! New BASF Analysis from March 22 delivers the answer:
The latest BASF figures speak for themselves: Urgent action needed for BASF investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 22.
BASF: Buy or sell? Read more here...









